Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05055518 Recruiting - Clinical trials for Advanced Solid Tumor

APL-102 Capsule in Patients With Advanced Solid Tumors

Start date: August 2, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.

NCT ID: NCT05052268 Active, not recruiting - Clinical trials for Advanced Solid Tumor

XTX202 in Patients With Advanced Solid Tumors

Start date: January 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

NCT ID: NCT05052255 Recruiting - Clinical trials for Advanced Solid Tumor

RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors

Start date: August 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.

NCT ID: NCT05051241 Completed - Clinical trials for Advanced Solid Tumor

A Study of GFH018 in Patients With Advanced Solid Tumors

Start date: August 30, 2019
Phase: Phase 1
Study type: Interventional

This is the first- in human study of GFH018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration. The study is designed to explore the safety/tolerability, pharmacokinetics, and MTD of GFH018 and to define a RP2D of GFH018.

NCT ID: NCT05048368 Not yet recruiting - Esophageal Cancer Clinical Trials

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Start date: December 30, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

NCT ID: NCT05043298 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

This is an open label Phase Ia/Ib trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of IBI360 monotherapy in Advanced or Metastatic Solid Tumors

NCT ID: NCT05038150 Recruiting - Clinical trials for Advanced Solid Tumor

Study of SGN1 in Patients With Advanced Solid Tumor

Start date: January 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. Patient Population:The treatment populations shall be patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.

NCT ID: NCT05036291 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Start date: October 1, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors

NCT ID: NCT05021367 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

Start date: September 23, 2021
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult patients with advanced solid tumors .The study was divided into phase Ia and phase Ib, Phase Ia: Dose escalation period, to evaluate the safety and tolerability of TQB3823 tablets, determine MTD;Phase Ib: Effectiveness exploration period, to expand the safe and effective dose group, and to recommend appropriate dosage and method for subsequent clinical research.

NCT ID: NCT05020119 Recruiting - Clinical trials for Advanced Solid Tumor

Neoantigen-expanded Autologous Immune Cell Therapy

Start date: April 9, 2021
Phase: Phase 1
Study type: Interventional

The investigators aim to investigate the patient's tumor neoantigen to generate "personalized cancer vaccine" and then to expand autologous dendritic cells-cytokine-induced killer cells (DC-CIK). The autologous DC-CIK will be cultured in vitro and re-infused into patients.